ASCO 2022 Conference Coverage
Playback speed
10 seconds
ASCO 2022 A Phase 1b/2 Study of the BET Inhibitor ZEN-3694 in Combination With Talazoparib for Treatment of Patients With TNBC Without gBRCA1/2 Mutations
By
ASCO 2022 Conference Coverage
FEATURING
Philippe Aftimos
By
ASCO 2022 Conference Coverage
FEATURING
Philippe Aftimos
37 views
July 26, 2022
Comments 0
Login to view comments.
Click here to Login
Breast